Enavate Sciences is an investment platform formed by Patient Square Capital in 2022 with $300 million to invest in and support the strategic growth of innovative therapeutic and enabling technology companies.
62% of their portfolio is in Biotech & Life Sciences. Deal activity increased 50% year-over-year (3 deals in the last 12 months). Average disclosed round size is $160.0M (across 24 rounds with reported amounts).
Portfolio
16
Fund Size
$300M
Top Stage
Series A
Last 12 Mo
3
Team
AP
Amar Patel
Biotech Investor
EF
Edd Fleming
Invest in therapeutic biotech companies
SN
Sara Nayeem
EVP, Investments
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
26 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Braveheart Bio | Unknown | $185M | Sep 2026 |
 Ambros Therapeutics | Series A | $125M | Aug 2026 |
 Aviceda | Series C | — | Jan 2026 |
| AAirNexis | Series A | $200M | Jan 2026 |
| Braveheart Bio | Unknown | $185M | Jan 2026 |
| AAviceda Therapeutics | Unknown | $207.5M | Jan 2026 |
| Ambros Therapeutics | Series A | $125M | Dec 2025 |
| Braveheart Bio | Series A | $185M | Nov 2025 |
| BBridgeBio Oncology Therapeutics | Unknown | $261M | Aug 2025 |
| AAviceda Therapeutics | Series C | — | Jan 2025 |
| BBridgeBio Oncology Therapeutics | Unknown | $260M | Jan 2025 |
| Ambros Therapeutics | Series A | $125M | Jan 2025 |
 Zenas BioPharma | Series C | $200M | May 2024 |
 BridgeBio Oncology Therapeutics (BBOT) | Growth | $200M | May 2024 |
 Sudo Biosciences | Series B | $147M | Jan 2024 |
 Sudo | Series B | $147M | Jan 2024 |
| Zenas BioPharma | Series C | $200M | Jan 2024 |
 OrsoBio | Series B | $67M | Jan 2024 |
| SSionna | Series C | $182M | Jan 2024 |
| OrsoBio | Series A | $60M | Nov 2023 |
| UUpstream Bio, Inc. | Series B | $200M | Jun 2023 |
| OrsoBio | Series A | $60M | Jan 2023 |
 AirNexis Therapeutics | Series A | $200M | — |
| CCamp4 | Series B | $100M | — |
| Zenas BioPharma | Series B | $118M | — |
Page 1 of 2
Top Co-Investors
Longitude Capital11 shared
OrbiMed10 shared
Wellington Management7 shared
Omega Funds7 shared
Frazier Life Sciences7 shared
Surveyor Capital5 shared
Andreessen Horowitz5 shared
SR One4 shared
Eventide Asset Management4 shared
Samsara BioCapital4 shared
Cormorant Asset Management3 shared
Catalio Capital Management3 shared
Jeito Capital3 shared
Logos Capital3 shared
Marshall Wace3 shared
Digitalis Ventures3 shared
Quan Funds3 shared
Pivotal Life Sciences3 shared
Fairmount Funds Management3 shared
Last updated: 7 October 2026